Dare Bioscience, Inc. quarterly report, Q1 FY2017

Dare Bioscience, Inc. (formerly Cerulean Pharma Inc.) — Q1 2017 Form 10-Q

Reporting period: Three months ended March 31, 2017. This filing was submitted by Cerulean Pharma Inc.; it describes a proposed transaction to acquire Dare Bioscience, Inc. and a contemplated change in the company’s business. The transactions were not yet closed as of the reporting date.

Business context and strategic transactions

Cerulean was a development-stage oncology company focused on its Dynamic Tumor Targeting Platform and had no product-sale revenue. In March 2017, it sold clinical candidates CRLX101 and CRLX301 and related rights to BlueLink for $1.5 million, received during the quarter. It agreed to sell its Platform to Novartis for $6.0 million, subject to stockholder approval and other closing conditions. Separately, Cerulean agreed to acquire all outstanding Dare Bioscience equity in a transaction expected to leave Dare’s selling stockholders with approximately 51%–70% of the combined company on a fully diluted basis; that transaction also required approvals and other conditions.

Cerulean announced a restructuring expected to reduce its workforce by approximately 58%, from 19 full-time-equivalent employees to eight. The plan was expected to be completed in Q2 2017. The filing reports 18 full-time employees as of March 31.

Key financial metrics

MetricQ1 2017 / March 31, 2017Comparable period / prior year-end
Revenue$1.192 million$0 in Q1 2016
Research and development expense$4.651 million$9.770 million in Q1 2016
General and administrative expense$3.587 million$3.118 million in Q1 2016
Net loss$6.339 million$13.542 million in Q1 2016
Net loss per share, basic and diluted$0.22$0.49 in Q1 2016
Operating cash use$10.000 million$13.260 million in Q1 2016
Cash and cash equivalents$12.028 million$34.950 million at December 31, 2016
Total assets$15.953 million$37.688 million at December 31, 2016
Loan payable$0$12.821 million at December 31, 2016
Accumulated deficit$207.019 million$200.680 million at December 31, 2016

Q1 revenue came from the Novartis research collaboration: $625,000 of recognized upfront-payment revenue and $567,000 for funded research activities. It was not product-sale revenue. Gross margin is not presented and is not a meaningful disclosed measure for this development-stage business.

Operating expenses were $6.738 million, including a $1.5 million gain on the BlueLink asset sale recorded as a reduction of expenses. The gain helped reduce the reported operating loss to $5.546 million. R&D expense declined 52%, primarily because of lower manufacturing, clinical-trial and personnel costs; G&A rose 15%, principally due to transaction-related legal expense. Other expense, net, was $793,000, largely reflecting interest and costs associated with repaying the Hercules loan.

Cash declined by $22.922 million during the quarter. Investing activities provided $1.5 million from the BlueLink sale; financing activities used $14.422 million, chiefly for $13.077 million of loan payments and a $1.407 million end-of-term charge. The company paid Hercules $12.4 million in March to settle and terminate the loan, leaving no loan payable at quarter-end.

Changes, outlook, risks and unusual items

  • Management estimated cash would be $4 million–$6 million at June 30, 2017 if neither the Novartis asset sale nor the Dare transaction had closed. It stated that no other significant liquidity sources were in place as of March 31.
  • The filing concludes that the company’s circumstances raised substantial doubt about its ability to continue as a going concern. Management warned that failure to secure a transaction or additional funding could require further cuts, suspension or termination of operations, or liquidation.
  • If the Dare transaction closed, the estimated “Net Cash” used to calculate ownership was $2.5 million–$4 million without the Novartis transaction and $8.5 million–$10 million with it. These are estimates, not completed transaction proceeds.
  • Cerulean paid $1.1 million in employee retention payments, recorded as prepaid at quarter-end; agreements could require up to an additional $1.6 million in change-in-control and severance payments.
  • CRLX101 had failed to meet the primary endpoint in two Phase 2 trials, including the renal-cell-carcinoma combination trial; Cerulean had discontinued development in that indication and sold both clinical candidates to BlueLink.
  • On May 5, 2017, NASDAQ notified the company that its share price had failed the $1.00 minimum-bid requirement for 30 consecutive business days. It had until November 1, 2017 to regain compliance, subject to exchange requirements.
  • Management expected R&D and G&A expenses to decrease in 2017 under the restructuring if the company did not resume platform development. Continuing the Platform, if the Novartis sale failed, would require new financing and potentially additional staff.

Most important facts for investors to verify

  • Whether stockholders and other required parties approved and completed the Dare acquisition and Novartis asset sale, and the final terms, timing and ownership impact.
  • Actual cash burn and liquidity after March 31, including whether the June 30 cash estimate was achieved and whether additional financing was obtained.
  • Whether the restructuring, retention and severance obligations were completed as described, and any further liabilities or transaction-related costs.
  • Whether NASDAQ minimum-bid compliance was regained and what effect any listing status change had on financing and trading liquidity.
  • Any subsequent developments affecting the going-concern conclusion, potential liquidation, or cash potentially available to stockholders after debts, reserves and contractual obligations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.